Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, Bouvenot G, Eschwége E
Institut National de la Santé et de la Recherche Médicale, Unité 21 and Faculté de Médecine Paris Sud, Villejuif, France.
JAMA. 1998 Feb 4;279(5):365-70. doi: 10.1001/jama.279.5.365.
The spread of drug-resistant Streptococcus pneumoniae in the community is a public health problem in developed and developing nations, but whether antibiotic use is responsible for the increase in drug resistance is not known.
To analyze the relationship between penicillin-resistant S pneumoniae (PRSp) pharyngeal carriage and characteristics of beta-lactam use.
Observational study of children attending 20 randomly sampled schools.
The Loiret, in the center of France.
A total of 941 children, 3 to 6 years old.
MAIN OUTCOME MEASURE(S): Pharyngeal carriage of S pneumoniae, antibiotic use, and medical events during the preceding 30 days. Pneumococcal penicillin G sodium minimal inhibitory concentrations and serotyping were performed.
Medical illnesses and the use of antibiotics were not associated with PRSp carriage. However, oral beta-lactam use was associated with an increased risk of PRSp carriage (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.1-8.3; P=.03). Children treated by low daily doses of an oral beta-lactam (defined as lower than clinical recommendations) had an increased risk of PRSp carriage, as compared with children who did not (OR, 5.9; 95% CI, 2.1-16.7; P=.002). A treatment of long duration (>5 days) with a beta-lactam was associated with an increased risk of PRSp carriage (OR, 3.5; 95% CI, 1.3-9.8; P=.02).
Our results suggest that a low daily dose and a long duration of treatment with an oral beta-lactam contribute to the selective pressure in promoting pharyngeal carriage of PRSp.
耐药性肺炎链球菌在社区中的传播在发达国家和发展中国家都是一个公共卫生问题,但抗生素的使用是否导致耐药性增加尚不清楚。
分析耐青霉素肺炎链球菌(PRSp)咽部携带情况与β-内酰胺类药物使用特征之间的关系。
对20所随机抽样学校的儿童进行观察性研究。
法国中部的卢瓦雷省。
共941名3至6岁的儿童。
前30天内肺炎链球菌的咽部携带情况、抗生素使用情况及医疗事件。进行肺炎球菌青霉素G钠最低抑菌浓度测定和血清分型。
疾病和抗生素使用与PRSp携带无关。然而,口服β-内酰胺类药物使用与PRSp携带风险增加有关(优势比[OR],3.0;95%置信区间[CI],1.1-8.3;P = 0.03)。与未接受治疗的儿童相比,接受低日剂量口服β-内酰胺类药物治疗(定义为低于临床推荐剂量)的儿童PRSp携带风险增加(OR,5.9;95%CI,2.1-16.7;P = 0.002)。β-内酰胺类药物长期治疗(>5天)与PRSp携带风险增加有关(OR,3.5;95%CI,1.3-9.8;P = 0.02)。
我们的结果表明,低日剂量和长期口服β-内酰胺类药物治疗会增加促进PRSp咽部携带的选择压力。